<DOC>
	<DOCNO>NCT00303888</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel , work different way stop growth tumor cell , either kill cell stop dividing . Phenoxodiol may help docetaxel work well make tumor cell sensitive drug . PURPOSE : This randomized phase I/II trial study side effect docetaxel give together either phenoxodiol placebo see well work treat patient recurrent advanced ovarian epithelial cancer , fallopian tube cancer , primary peritoneal cavity cancer .</brief_summary>
	<brief_title>Docetaxel With Without Phenoxodiol Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer , Fallopian Tube Cancer , Primary Peritoneal Cavity Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety tolerability combination therapy comprise phenoxodiol docetaxel patient recurrent persistent advanced ovarian epithelial , fallopian tube , primary peritoneal cavity cancer . Secondary - Determine effect phenoxodiol toxicity docetaxel use weekly treatment regimen . - Determine combination therapy comprise phenoxodiol docetaxel efficacious docetaxel therapy alone . - Determine combination therapy comprise phenoxodiol docetaxel affect blood level either drug . - Determine phenotypic difference tumor cell `` responder '' `` non-responders . '' OUTLINE : This randomize , placebo-controlled , double-blind study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive docetaxel IV 1 hour day 1 , 8 , 15 oral placebo three time daily day 1-21 . - Arm II : Patients receive oral phenoxodiol three time daily day 1-21 docetaxel arm I . Treatment arm repeat every 4 week 12 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow monthly 6 month , every 3 month 1 year , annually thereafter . PROJECTED ACCRUAL : A total 60 patient accrue study . 3/31/2017 NOTE This study terminate 10/2009 due lack enrollment . The study never progress Phase 2 .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis 1 following : Ovarian epithelial cancer Fallopian tube cancer Primary peritoneal cavity cancer Recurrent advance disease Eligible secondline fifthline chemotherapy Received platinum taxane combination chemotherapy firstline treatment disease recurrence &gt; 6 month conclusion therapy No demonstrate refractoriness resistance weekly docetaxel Meets 1 follow criterion : Doubling blood level CA125 past 6 month CA125 level ≥ 2 time upper limit normal ( ULN ) Measurable disease define ≥ 1 lesion ≥ 20 mm conventional technique ≥ 10 mm spiral CT scan No active CNS metastases Prior CNS metastases allow provide treated radiation therapy disease stable 4 week PATIENT CHARACTERISTICS : Karnofsky performance score ≥ 60 % Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study treatment Life expectancy ≥ 3 month Creatinine ≤ 1.5 mg/dL Transaminases ≤ 3 time upper limit normal ( ULN ) Bilirubin normal Platelet count &gt; 100,000/mm^3 WBC &gt; 3,000/mm^3 Neutrophil count &gt; 1,500/mm^3 Hemoglobin ≥ 8.0 g/dL Peripheral neuropathy ≤ grade 1 Relative proportion AST , ALT , alkaline phosphatase accord 1 follow criterion : Alkaline phosphatase ( AP ) normal AND AST/ALT ≤ 5 time ULN AP ≤ 2.5 time ULN AND AST/ALT ≤ 1.5 time ULN AP ≤ 5 time ULN AND AST/ALT normal No active infection No concurrent severe and/or uncontrolled medical disease ( e.g. , uncontrolled diabetes , hypertension , ischemic heart disease , congestive heart failure ) No history chronic active hepatitis cirrhosis No history severe hypersensitivity docetaxel drug formulate polysorbate 80 PRIOR CONCURRENT THERAPY : See Disease Characteristics No investigational agent within 4 week prior study entry Recovered prior antineoplastic therapy No concurrent investigational drug No concurrent chemotherapy , radiotherapy , immunotherapy , hormonal antitumor therapy Concurrent localize radiation therapy allow control local disease complication ( e.g. , bone metastasis ) represent general progression disease status No concurrent grapefruit grapefruit juice No concurrent amifostine</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>stage IIIA ovarian epithelial cancer</keyword>
	<keyword>stage IIIB ovarian epithelial cancer</keyword>
	<keyword>stage IIIC ovarian epithelial cancer</keyword>
	<keyword>recurrent primary peritoneal cavity cancer</keyword>
	<keyword>stage IIIA primary peritoneal cavity cancer</keyword>
	<keyword>stage IIIB primary peritoneal cavity cancer</keyword>
	<keyword>stage IIIC primary peritoneal cavity cancer</keyword>
	<keyword>stage IV primary peritoneal cavity cancer</keyword>
	<keyword>recurrent fallopian tube cancer</keyword>
	<keyword>stage IIIA fallopian tube cancer</keyword>
	<keyword>stage IIIB fallopian tube cancer</keyword>
	<keyword>stage IIIC fallopian tube cancer</keyword>
	<keyword>stage IV fallopian tube cancer</keyword>
</DOC>